8-K: Aspire Biopharma Renames, Approves $10M Share Buyback

Aspire Biopharma Holdings, Inc. has officially changed its name to Aspire-Lakewood Holdings, Inc. and announced a $10 million share repurchase program, signaling confidence in its financial strength and future growth.

Summary

• Aspire Biopharma Holdings, Inc. has officially changed its name to Aspire-Lakewood Holdings, Inc., effective September 8, 2026.
• The company announced a $10 million common stock repurchase program, effective September 9, 2026.
• This expanded program reflects confidence in the company's long-term strategy and strong free cash flow generation.
• The decision is supported by the performance of the newly acquired Dura Control Systems Corp. (DCSC).
• DCSC reported approximately $209.5 million in revenue and $22.3 million in Adjusted EBITDA for the full year 2025.
• For the first six months of 2026, DCSC generated approximately $103.9 million in revenue and $10.5 million in Adjusted EBITDA.
• The company had approximately 1.5 million common shares outstanding as of September 8, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, indicating management confidence and a commitment to shareholder returns, supported by recent acquisition performance.

Positives

• The company has officially changed its name to Aspire-Lakewood Holdings, Inc., reflecting a potential strategic shift or integration.
• A new $10 million share repurchase program has been authorized, demonstrating management's belief in the company's undervaluation and commitment to shareholder returns.
• The repurchase program is supported by strong free cash flow generation and the successful acquisition of Dura Control Systems Corp. (DCSC).
• DCSC contributed significant revenue ($209.5 million in 2025) and Adjusted EBITDA ($22.3 million in 2025) to the company's financial profile.
• DCSC's performance continued into 2026 with $103.9 million in revenue and $10.5 million in Adjusted EBITDA for the first six months.
• Management views the current share price as not reflecting the company's financial strength or long-term growth opportunity.

Negatives

• The filing does not contain any explicitly negative financial results or operational setbacks.
• The forward-looking statements section highlights numerous risks that could impact actual results, including potential delays in development, regulatory actions, and integration challenges with DCSC.

Risks

• The planned share repurchases are subject to change, may not be completed as planned, and could be suspended, delayed, or discontinued based on market conditions, capital allocation planning, cash balances, other demands for cash, economic conditions, and management discretion.
• The actual number of shares repurchased, and the timing and cost, will depend on share price and market conditions and may differ materially from expectations.
• Share repurchases may not ultimately enhance shareholder value.
• Risks related to DCSC's business include dependence on key automotive OEM customers, exposure to cyclical conditions in the global automotive industry, potential liabilities associated with operations and intellectual property, and challenges in integrating DCSC's operations.
• There is a risk that anticipated financial benefits from the DCSC acquisition may not be realized.
• The business operations and strategies of DCSC and Aspire may diverge.
• Clinical trial results for drug candidates may not demonstrate efficacy and safety to the satisfaction of regulatory authorities, potentially causing additional costs or delays, or preventing completion of development and commercialization.
• Actions of regulatory agencies could affect the initiation, timing, and progress of clinical trials and marketing approval.

Future Outlook

The company expresses confidence in its long-term strategy and strong free cash flow generation, supporting the share repurchase program. The acquisition of DCSC is seen as a catalyst for shareholder value. Management is acting decisively to accelerate returns while continuing to invest in the business. The company also mentions developing a patent-pending delivery technology for various active pharmaceutical ingredients.

Management Comments

• "Our strengthened liquidity profile and robust cash generation options give us significant financial flexibility to plan with conviction on behalf of our shareholders."
• "Aspires acquisition of DCSC marks a significant achievement and a powerful catalyst for shareholder value."
• "DCSC provides immediate, scaled revenue and strong, Adjusted EBITDA into our financial profile, and we do not believe our current share price reflects that position or the strength of our business fundamentals."
• "We are preparing and acting decisively in an effort to accelerate returns to our shareholders while continuing to invest in our business."
• "Our disciplined capital allocation remains core to how we create long-term shareholder value."

Industry Context

StockSavvy.ai notes that the automotive supplier industry, particularly for electronic and mechanical control systems, is experiencing shifts due to vehicle electrification, safety, and sustainability trends. DCSC's focus on these areas positions it well, but also exposes it to the cyclical nature of the automotive sector and intense competition. The company's biopharmaceutical development adds a diversification element, though it operates in a highly regulated and capital-intensive industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through share price appreciation driven by the repurchase program and increased confidence in the company's valuation. However, the actual impact depends on market conditions and the success of the repurchases.
• Employees: The company's continued investment in its business and strategic direction may provide job security and growth opportunities.
• Creditors: The company's stated strong free cash flow generation and liquidity profile suggest a stable ability to meet financial obligations.

Next Steps

• The company will continue to evaluate market conditions and its performance to determine the timing and extent of share repurchases under the new program.
• The company will continue to invest in its business.
• The company is developing a patent-pending delivery technology for various active pharmaceutical ingredients.

Key Dates

Recommendation

The $10 million share repurchase program signals management's confidence, and the acquisition of DCSC has demonstrably improved revenue and profitability. However, the significant forward-looking risks outlined, particularly concerning clinical trials and integration, warrant a cautious approach. The company's strategic direction is evolving, and further performance data is needed to justify a more aggressive stance.

Keywords

share repurchase, name change, Dura Control Systems Corp, Adjusted EBITDA, automotive supplier, financial flexibility, capital allocation, Nasdaq